Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660881 · ClinicalTrials.gov registry record · Phase 2
Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT00660881: Completed Phase 2 study, sponsored by UCB Pharma.
NCT00660881 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 210 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00660881, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the safety of epratuzumab in patients with SLE.
Interventions
- BIOLOGICAL Epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00660881 record still lists
NCT00660881 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% higher).
The record links to 0 conditions, and to 1 intervention - of which Epratuzumab is the first listed.
NCT00660881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00660881 about?
NCT00660881 is a clinical study titled "Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease". The primary objective of the study is to assess the safety of epratuzumab in patients with SLE.
What is the current status of trial NCT00660881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2008-05. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00660881?
The interventions under investigation include: Epratuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00660881?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00660881's enrollment target sits among peer trials
210 290th of 2000 higher than 1,707 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia